Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gefitinib - AstraZeneca

Next Previous
X
Search
Drug Profile

Gefitinib - AstraZeneca

Alternative Names: Iressa; ZD-1839

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Brigham and Women's Hospital; Dana-Farber Cancer Institute; Hutchison MediPharma; Massachusetts General Hospital; MedImmune; University of Texas M. D. Anderson Cancer Center
  • Class Amines; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Morpholines; Phenyl ethers; Quinazolines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Salivary gland cancer
  • No development reported Head and neck cancer
  • Discontinued Bladder cancer; Brain metastases; Breast cancer; Colorectal cancer; Glioblastoma; Renal cell carcinoma; Thyroid cancer

Most Recent Events

  • 09 Jun 2021 Hutchison MediPharma has been acquired and merged into HUTCHMED
  • 31 Dec 2020 AstraZeneca completes a phase III clinical trial for Non-small cell lung cancer (Adjuvant therapy) in Japan (PO, Tablet) (UMIN000006252)
  • 28 Jun 2020 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, First-line therapy, Late-stage disease, Newly diagnosed) in USA (PO, Tablet)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top